Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1977 1
1978 1
1979 1
1982 1
1983 2
1984 2
1985 1
1987 3
1988 2
1989 2
1990 1
1991 5
1992 3
1993 3
1994 8
1995 3
1996 6
1997 9
1998 4
1999 12
2000 11
2001 10
2002 8
2003 19
2004 17
2005 27
2006 28
2007 31
2008 26
2009 27
2010 19
2011 27
2012 25
2013 18
2014 23
2015 22
2016 14
2017 15
2018 23
2019 14
2020 11
2021 15
2022 12
2023 19
2024 21
2025 12
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

523 results

Results by year

Citations

5 articles found by citation matching
Show all

Search results

Filters applied: . Clear all
Page 1
Testosterone in women--the clinical significance.
Davis SR, Wahlin-Jacobsen S. Davis SR, et al. Lancet Diabetes Endocrinol. 2015 Dec;3(12):980-92. doi: 10.1016/S2213-8587(15)00284-3. Epub 2015 Sep 7. Lancet Diabetes Endocrinol. 2015. PMID: 26358173 Review.
The primary indication for the prescription of testosterone for women is loss of sexual desire, which causes affected women substantial concern. ...Unmet needs include the availability of approved testosterone formulations for women and studies …
The primary indication for the prescription of testosterone for women is loss of sexual desire, which causes affected women …
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Bhasin S, et al. J Clin Endocrinol Metab. 2018 May 1;103(5):1715-1744. doi: 10.1210/jc.2018-00229. J Clin Endocrinol Metab. 2018. PMID: 29562364 Free article.
We recommend against starting T therapy in patients who are planning fertility in the near term or have any of the following conditions: breast or prostate cancer, a palpable prostate nodule or induration, prostate-specific antigen level > 4 ng/mL, prostate-speci …
We recommend against starting T therapy in patients who are planning fertility in the near term or have any of the following conditions: …
The Effect of Diet on Breast Cancer Recurrence: The DIANA-5 Randomized Trial.
Berrino F, Villarini A, Gargano G, Krogh V, Grioni S, Bellegotti M, Venturelli E, Raimondi M, Traina A, Zarcone M, Amodio R, Mano MP, Johansson H, Panico S, Santucci de Magistris M, Barbero M, Gavazza C, Mercandino A, Consolaro E, Galasso R, Del Riccio L, Bassi MC, Simeoni M, Premoli P, Pasanisi P, Bonanni B, Bruno E. Berrino F, et al. Clin Cancer Res. 2024 Mar 1;30(5):965-974. doi: 10.1158/1078-0432.CCR-23-1615. Clin Cancer Res. 2024. PMID: 37847493 Free PMC article. Clinical Trial.
PURPOSE: The DIANA-5 randomized controlled trial assessed the effectiveness of a diet based on Mediterranean and macrobiotic traditions (macro-Mediterranean diet) in reducing breast cancer recurrence. PATIENTS AND METHODS: The DIANA-5 study involved 1,542 patients w …
PURPOSE: The DIANA-5 randomized controlled trial assessed the effectiveness of a diet based on Mediterranean and macrobiotic traditions (mac …
Non-genetic factors and breast cancer: an umbrella review of meta-analyses.
Yiallourou A, Pantavou K, Markozannes G, Pilavas A, Georgiou A, Hadjikou A, Economou M, Christodoulou N, Letsos K, Khattab E, Kossyva C, Constantinou M, Theodoridou M, Piovani D, Tsilidis KΚ, Bonovas S, Nikolopoulos GK. Yiallourou A, et al. BMC Cancer. 2024 Jul 26;24(1):903. doi: 10.1186/s12885-024-12641-8. BMC Cancer. 2024. PMID: 39061008 Free PMC article.
BACKGROUND: Previous research has found associations between various non-genetic factors and breast cancer (BrCa) risk. This study summarises and appraises the credibility of the available evidence on the association between non-genetic factors and BrCa ri …
BACKGROUND: Previous research has found associations between various non-genetic factors and breast cancer (BrCa) risk. …
Breast cancer risk in postmenopausal women using testosterone in combination with hormone replacement therapy.
Bitzer J, Kenemans P, Mueck AO; FSDeducation Group. Bitzer J, et al. Maturitas. 2008 Mar 20;59(3):209-18. doi: 10.1016/j.maturitas.2008.01.005. Epub 2008 Mar 14. Maturitas. 2008. PMID: 18343056 Review.
The purpose of this study is to review the available clinical data on the impact of exogenous testosterone containing postmenopausal hormone therapy on breast cancer risk. METHODS: A literature search was done in MEDLINE (1969-July 2007) and in additio …
The purpose of this study is to review the available clinical data on the impact of exogenous testosterone containing postmenopausal …
The Impact of Exogenous Testosterone on Breast Cancer Risk in Transmasculine Individuals.
Gurrala RR, Kumar T, Yoo A, Mundinger GS, Womac DJ, Lau FH. Gurrala RR, et al. Ann Plast Surg. 2023 Jan 1;90(1):96-105. doi: 10.1097/SAP.0000000000003321. Ann Plast Surg. 2023. PMID: 36534108
BACKGROUND: Exogenous testosterone is vital to gender-affirming therapy for transmasculine individuals. Testosterone may be implicated in breast cancer (BCa) because it can activate androgen and estrogen receptors. To further explore this risk, …
BACKGROUND: Exogenous testosterone is vital to gender-affirming therapy for transmasculine individuals. Testosterone may be im …
Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial.
Cuzick J, Chu K, Keevil B, Brentnall AR, Howell A, Zdenkowski N, Bonanni B, Loibl S, Holli K, Evans DG, Cummings S, Dowsett M. Cuzick J, et al. Lancet Oncol. 2024 Jan;25(1):108-116. doi: 10.1016/S1470-2045(23)00578-8. Epub 2023 Dec 6. Lancet Oncol. 2024. PMID: 38070530 Free article. Clinical Trial.
BACKGROUND: An increased risk of breast cancer is associated with high serum concentrations of oestradiol and testosterone in postmenopausal women, but little is known about how these hormones affect response to endocrine therapy for breast …
BACKGROUND: An increased risk of breast cancer is associated with high serum concentrations of oestradiol and testos …
Using human genetics to understand the disease impacts of testosterone in men and women.
Ruth KS, Day FR, Tyrrell J, Thompson DJ, Wood AR, Mahajan A, Beaumont RN, Wittemans L, Martin S, Busch AS, Erzurumluoglu AM, Hollis B, O'Mara TA; Endometrial Cancer Association Consortium; McCarthy MI, Langenberg C, Easton DF, Wareham NJ, Burgess S, Murray A, Ong KK, Frayling TM, Perry JRB. Ruth KS, et al. Nat Med. 2020 Feb;26(2):252-258. doi: 10.1038/s41591-020-0751-5. Epub 2020 Feb 10. Nat Med. 2020. PMID: 32042192 Free PMC article.
For example, a genetically determined 1 s.d. higher testosterone increases the risks of type 2 diabetes (odds ratio (OR) = 1.37 (95% confidence interval (95% CI): 1.22-1.53)) and polycystic ovary syndrome (OR = 1.51 (95% CI: 1.33-1.72)) in women, but reduces type 2 …
For example, a genetically determined 1 s.d. higher testosterone increases the risks of type 2 diabetes (odds ratio (OR) = 1.37 (95% …
Testosterone and breast cancer prevention.
Glaser R, Dimitrakakis C. Glaser R, et al. Maturitas. 2015 Nov;82(3):291-5. doi: 10.1016/j.maturitas.2015.06.002. Epub 2015 Jun 24. Maturitas. 2015. PMID: 26160683 Free article. Review.
Testosterone (T) is the most abundant biologically active hormone in women. Androgen receptors (AR) are located throughout the body including the breast where T decreases tissue proliferation. However, T can be aromatized to estradiol (E2), which increases pr …
Testosterone (T) is the most abundant biologically active hormone in women. Androgen receptors (AR) are located throughout the …
Causes and Consequences of Polycystic Ovary Syndrome: Insights From Mendelian Randomization.
Zhu T, Goodarzi MO. Zhu T, et al. J Clin Endocrinol Metab. 2022 Feb 17;107(3):e899-e911. doi: 10.1210/clinem/dgab757. J Clin Endocrinol Metab. 2022. PMID: 34669940 Free PMC article. Review.
CONTEXT: Although polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting women of reproductive age, risk factors that may cause the syndrome are poorly understood. ...In turn, PCOS may increase the risk of estrogen receptor-positive b …
CONTEXT: Although polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting women of reproductive age, risk …
523 results